Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Community Practice Connections™: Navigating a New Era of Food Allergy Management
View More
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | Arizona
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Nevada
View More
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Missouri
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | New Mexico
View More
Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 66th ASH Annual Meeting
April 26-27, 2025
Register Now!
Vaxart Launches Dosing in Expanded 10,000-Participant Phase 2b Trial for Oral COVID-19 Vaccine
Following a positive safety review, Vaxart advances its needle-free, room-temperature stable oral vaccine candidate with government-backed funding and a year-long follow-up study.
Company Receives NIH Grant For Novel Investigational Antibiotic to Combat ‘Super Gonorrhea’
May 27th 2025TAXIS Pharmaceuticals announced it received a $2.9 million dollar federal grant, which will allow the company to further advance its efforts with its dihydrofolate reductase inhibitors (DHFRIs) for the rapidly spreading and antibiotic-resistant strain of Neisseria gonorrhoeae.